Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Mastrantoni L, Chiaravalli M, Spring A, Beccia V, Di Bello A, Bagalà C, Bensi M, Barone D, Trovato G, Caira G, Giordano G, Bria E, Tortora G, Salvatore L. Mastrantoni L, et al. Among authors: bria e. Lancet Oncol. 2024 Nov 11:S1470-2045(24)00511-4. doi: 10.1016/S1470-2045(24)00511-4. Online ahead of print. Lancet Oncol. 2024. PMID: 39542008
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis.
Mastrantoni L, Beccia V, Caira G, Trovato G, Calegari MA, Basso M, Salvatore L, Pozzo C, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Among authors: bria e. Crit Rev Oncol Hematol. 2023 Nov;191:104106. doi: 10.1016/j.critrevonc.2023.104106. Epub 2023 Sep 1. Crit Rev Oncol Hematol. 2023. PMID: 37659764 Free article. Review.
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Ciccarese C, Iacovelli R, Bria E, Mosillo C, Bimbatti D, Fantinel E, Bisogno I, Brunelli M, Tortora G. Ciccarese C, et al. Among authors: bria e. Semin Oncol. 2019 Feb;46(1):65-72. doi: 10.1053/j.seminoncol.2019.01.001. Epub 2019 Jan 14. Semin Oncol. 2019. PMID: 30665685
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L, Orlandi A, Palazzo A, Garufi G, Fabi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: bria e. EClinicalMedicine. 2023 Jan 20;56:101824. doi: 10.1016/j.eclinm.2023.101824. eCollection 2023 Feb. EClinicalMedicine. 2023. PMID: 36713467 Free PMC article.
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials.
Mastrantoni L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, Pannunzio S, Cannizzaro MC, Di Bello A, Fabi A, Palazzo A, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Among authors: bria e. Ther Adv Med Oncol. 2023 May 29;15:17588359231173180. doi: 10.1177/17588359231173180. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37284523 Free PMC article.
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis.
Mastrantoni L, Giordano G, Vita E, Horn G, Russo J, Orlandi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: bria e. Cancer Treat Res Commun. 2024 Sep 6;41:100842. doi: 10.1016/j.ctarc.2024.100842. Online ahead of print. Cancer Treat Res Commun. 2024. PMID: 39260066 Free article. Review.
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
Salvatore L, Bria E, Sperduti I, Hinke A, Hegewisch-Becker S, Aparicio T, Le Malicot K, Boige V, Koeberle D, Baertschi D, Dietrich D, Tortora G, Arnold D. Salvatore L, et al. Among authors: bria e. Cancer Treat Rev. 2021 Jun;97:102202. doi: 10.1016/j.ctrv.2021.102202. Epub 2021 Mar 30. Cancer Treat Rev. 2021. PMID: 33838596 Free article. Review.
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma.
Trestini I, Carbognin L, Peretti U, Sperduti I, Caldart A, Tregnago D, Avancini A, Auriemma A, Orsi G, Pilotto S, Frulloni L, Capurso G, Bria E, Reni M, Tortora G, Milella M. Trestini I, et al. Among authors: bria e. Front Oncol. 2021 Sep 9;11:688889. doi: 10.3389/fonc.2021.688889. eCollection 2021. Front Oncol. 2021. PMID: 34568019 Free PMC article.
406 results